Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors-Reference-Cited by-同舟云学术

Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors

Published:2021 Issue:10 Volume:12 Page:1722-1730
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Bai Bing¹²,Arutyunova Elena³⁴,Khan Muhammad Bashir³,Lu Jimmy²⁴^ORCID,Joyce Michael A.²⁴^ORCID,Saffran Holly A.²⁴,Shields Justin A.²⁴^ORCID,Kandadai Appan Srinivas¹²,Belovodskiy Alexandr¹²^ORCID,Hena Mostofa¹²,Vuong Wayne⁵,Lamer Tess⁵^ORCID,Young Howard S.⁴,Vederas John C.⁵^ORCID,Tyrrell D. Lorne¹²⁴,Lemieux M. Joanne³⁴^ORCID,Nieman James A.¹²^ORCID

Affiliation:

1. Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada

2. Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada

3. Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada

4. Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada

5. Department of Chemistry, University of Alberta, Edmonton, Alberta, T6G 2G2, Canada

Abstract

This article describes peptidomimetic SARS-CoV-2 3CLpro inhibitors with a nitrile warhead with in vitro antiviral inhibition. Superior selectivity was observed for the nitrile warhead compared to the aldehyde against 3 human cathepsins (B, S and L).

Funder

Alberta Innovates

Canadian Institutes of Health Research

Basic Energy Sciences

Biological and Environmental Research

National Institute of General Medical Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/MD/D1MD00247C

Reference52 articles.

1. World Health Organization , http://www.who.int/emergencies/diseases/novel-coronavirus-2019 , (accessed June 14, 2021 )

2. The journey of remdesivir: from Ebola to COVID-19

3. US Food and Drug Administration , https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 , (accessed February 6, 2021)

4. Molecular Epidemiology of Human Coronavirus OC43 Reveals Evolution of Different Genotypes over Time and Recent Emergence of a Novel Genotype due to Natural Recombination

5. Centers for Disease Control and Prevention, https://www.cdc.gov/coronavirus/types.html , (accessed February 6, 2021)

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity;ACS Pharmacology & Translational Science;2024-01-19

2. On the origins of SARS-CoV-2 main protease inhibitors;RSC Medicinal Chemistry;2024

3. Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors;Chemical Biology & Drug Design;2023-12-11

4. Discovery of SARS‐CoV‐2 Inhibitors Featuring Novel Histidine α‐Nitrile Motif;Chemistry & Biodiversity;2023-11-15

5. The Effect of Deuteration and Homologation of the Lactam Ring of Nirmatrelvir on Its Biochemical Properties and Oxidative Metabolism;ACS Bio & Med Chem Au;2023-11-15